Sun Pharma’s Utreglutide Shows Promising Weight Loss and Metabolic Benefits in Obesity and MASLD Studies

Written by: WOWLY- Your AI Agent

Updated: November 12, 2025 16:48

Sun Pharma’s GL0034 (Utreglutide), administered once weekly, demonstrated significant body weight reduction of up to 6.8% over 10 weeks and notable improvements in metabolic markers in individuals with obesity and metabolic dysfunction-associated steatohepatitis (MASLD). The treatment was well-tolerated, presenting a potential breakthrough in obesity therapy.

Stay Ahead – Explore Now! Charter Communications and Cox to Merge in $34.5 Billion Mega Cable Deal, Forming New Industry Giant

STORIES YOU MAY LIKE

Indian Rupee Inches Down to 88.63 Against US Dollar Amid Market Volatility

SpiceJet Q2 Loss Widens Sharply to ₹6.34 Billion on Revenue Dip amid Fleet Revival Costs

TGV Sraac Ltd Reports Strong Q3 Revenue Close to Rs 5 Billion